Compass Therapeutics | 8-K: FY2025 Q2 Revenue: USD 0
Revenue: As of FY2025 Q2, the actual value is USD 0.
EPS: As of FY2025 Q2, the actual value is USD -0.14.
EBIT: As of FY2025 Q2, the actual value is USD -21.07 K, beating the estimate of USD -18.33 M.
Financial Results
Net Loss: Compass Therapeutics, Inc. reported a net loss of $19.9 million or $0.14 per share for the quarter ended June 30, 2025, compared to a net loss of $13.1 million or $0.10 per share for the same period in 2024. For the six months ended June 30, 2025, the net loss was $36.5 million or $0.26 per share, compared to $23.9 million or $0.17 per share for the same period in 2024.
Research and Development (R&D) Expenses: R&D expenses were $16.4 million for the quarter ended June 30, 2025, an increase of $5.2 million or 47% from $11.2 million in the same period in 2024. For the six months ended June 30, 2025, R&D expenses were $29.5 million, up $8.8 million or 42% from $20.7 million in the same period in 2024.
General and Administrative (G&A) Expenses: G&A expenses remained stable at $4.7 million for the quarters ended June 30, 2025, and 2024. For the six months ended June 30, 2025, G&A expenses were $9.6 million, an increase of $1.6 million or 20% from $8.0 million in the same period in 2024.
Cash Flow
- Cash Position: As of June 30, 2025, Compass Therapeutics had cash and marketable securities totaling $101 million, compared to $127 million as of December 31, 2024. The company used $25 million of net cash in operating activities during the first six months of 2025, and the cash runway is expected to extend into 2027.
Unique Metrics
CTX-10726 (PD-1 x VEGF-A): Superior PD-1 inhibition and tumor control vs ivonescimab in mouse models. IND on track for Q4 with commercial scale manufacturing yields.
CTX-8371 (PD-1 x PD-L1): 100% and >90% reductions in target tumor burden in Phase 1 study. Two confirmed PRs: one in NSCLC + one in triple-negative breast cancer. Cohort expansions planned in these indications.
Tovecimig (DLL4 x VEGF-A): Fewer pooled deaths (overall survival events) than projected. Believed to be affecting overall survival.
Outlook / Guidance
- Compass Therapeutics expects to analyze secondary endpoints, including overall survival, for the tovecimig Phase 2⁄3 study in Q1 2026 due to fewer deaths than projected. The company plans to initiate cohort expansions for CTX-8371 in Q4 2025 and submit an IND for CTX-10726 in Q4 2025, with clinical data expected in 2026.
